H.C. Wainwright Sticks to Their Buy Rating for BioDelivery (BDSI)


H.C. Wainwright analyst Oren Livnat maintained a Buy rating on BioDelivery (NASDAQ: BDSI) today and set a price target of $4. The company’s shares closed yesterday at $2.90.

According to TipRanks.com, Livnat has currently no stars on a ranking scale of 0-5 stars, with an average return of -5.0% and a 46.5% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Zynerba Pharmaceuticals, Pacira Pharmaceuticals, and Jazz Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for BioDelivery with a $4 average price target, implying a 37.9% upside from current levels. In a report released yesterday, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $4.50 price target.

.

See today’s analyst top recommended stocks >>

Based on BioDelivery’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $10.71 million. In comparison, last year the company had a GAAP net loss of $14.88 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BioDelivery Sciences International, Inc. is a pharmaceutical company, which engages in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. It focuses on pharmaceutical products in the areas of pain management and addiction.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts